{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:37:17Z","timestamp":1773938237424,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021555","name":"Vaccitech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cmi.2025.09.020","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:30:44Z","timestamp":1759008644000},"page":"41-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between COVID-19 vaccine immunogenicity and protection against infection and severe disease in clinically vulnerable patient populations: a systematic review and meta-analysis of observational studies"],"prefix":"10.1016","volume":"32","author":[{"given":"Maria","family":"Danysz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rute Cardoso","family":"De Aguiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hema","family":"Pindolia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"Spensley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elen","family":"Ashmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Frumento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nad\u00e8ge","family":"Haouidji-Javaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Iles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Rolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Uwenedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hollie","family":"Wagg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean H.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Willicombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.09.020_bib1","article-title":"Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: National prospective cohort study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.09.020_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072976","article-title":"Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): Cohort study","volume":"381","author":"Hippisley-Cox","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.09.020_bib3","article-title":"Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: Self-controlled case series study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.09.020_bib4","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","article-title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: Pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales","volume":"400","author":"Agrawal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.09.020_bib5","article-title":"Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: A cohort study of 28 million people in France","volume":"19","author":"Semenzato","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.cmi.2025.09.020_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.40037","article-title":"Factors associated with severe COVID-19 among vaccinated adults treated in US Veterans Affairs Hospitals","volume":"5","author":"Vo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2025.09.020_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41467-022-28527-x","article-title":"Population antibody responses following COVID-19 vaccination in 212,102 individuals","volume":"13","author":"Ward","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.09.020_bib8","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41591-023-02414-4","article-title":"SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease","volume":"29","author":"Barnes","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2025.09.020_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41541-024-00898-w","article-title":"Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland","volume":"9","author":"Macdonald","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.cmi.2025.09.020_bib10","series-title":"COVID-19: The green book, chapter 14a","year":"2025"},{"key":"10.1016\/j.cmi.2025.09.020_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamasurg.2021.0546","article-title":"PRISMA reporting guidelines for meta-analyses and systematic reviews","volume":"156","author":"Arya","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cmi.2025.09.020_bib12","series-title":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"GA Wells","year":"2021"},{"key":"10.1016\/j.cmi.2025.09.020_bib13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence\u2014Imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2025.09.020_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cmi.2025.09.020_bib15","series-title":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013)","year":"2013"},{"key":"10.1016\/j.cmi.2025.09.020_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(24)02560-1","article-title":"Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: The MELODY study","volume":"405","author":"Mumford","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.09.020_bib17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaoncol.2022.5974","article-title":"Association of SARS-CoV-2 spike protein antibody vaccine response with infection severity in patients with cancer: A national COVID cancer cross-sectional evaluation","volume":"9","author":"Lee","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cmi.2025.09.020_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-022-01275-7","article-title":"SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders","volume":"15","author":"Pinana","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.cmi.2025.09.020_bib19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/v16010114","article-title":"Incidence and severity of COVID-19 in relation to anti-receptor-binding domain IgG antibody level after COVID-19 vaccination in kidney transplant recipients","volume":"16","author":"Messchendorp","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.09.020_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12882-024-03560-8","article-title":"A prospective observational cohort study of covid-19 epidemiology and vaccine seroconversion in South Western Sydney, Australia, during the 2021-2022 pandemic period","volume":"25","author":"Potter","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.cmi.2025.09.020_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1280416","article-title":"Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: A prospective study","volume":"13","author":"Nelli","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.cmi.2025.09.020_bib22","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.3390\/curroncol30050386","article-title":"Effects of antibody response after booster vaccination on SARS-CoV-2 breakthrough infections and disease outcomes in advanced cancer patients: A prospective analysis of the vax-on-third study","volume":"30","author":"Nelli","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cmi.2025.09.020_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3343\/alm.2024.44.1.64","article-title":"Association between low anti-spike antibody levels after the third dose of SARS-CoV-2 vaccination and hospitalization due to symptomatic breakthrough infection in kidney transplant recipients","volume":"44","author":"Han","year":"2024","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.cmi.2025.09.020_bib24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/13524585231185247","article-title":"Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination","volume":"29","author":"Zaloum","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.cmi.2025.09.020_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003545","article-title":"Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: Identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study","volume":"10","author":"\u00d8rbo","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.cmi.2025.09.020_bib26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1186\/s12879-024-09861-5","article-title":"Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants","volume":"24","author":"Chalouni","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.020_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126547","article-title":"Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer","volume":"46","author":"Body","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2025.09.020_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.19126","article-title":"Immunogenicity and clinical effectiveness of mRNA vaccine booster against SARS-CoV-2 Omicron in patients with haematological malignancies: A national prospective cohort study","volume":"204","author":"Kevlicius","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2025.09.020_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1405217","article-title":"Unbiased immunome characterisation correlates with COVID-19 mRNA vaccine failure in immunocompromised adults","volume":"15","author":"H-Vazquez","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.09.020_bib30","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.3390\/cancers15112993","article-title":"Antibody response to the SARS-CoV-2 vaccine and COVID-19 vulnerability during the omicron pandemic in patients with CLL: Two-year follow-up of a multicenter study","volume":"15","author":"Mauro","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cmi.2025.09.020_bib31","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s12185-023-03550-w","article-title":"A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma","volume":"117","author":"Suzuki","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cmi.2025.09.020_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2163785","article-title":"RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies","volume":"12","author":"Bigenwald","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cmi.2025.09.020_bib33","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/jha2.544","article-title":"Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706)","volume":"3","author":"Bossi","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.cmi.2025.09.020_bib34","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1002\/ajh.26373","article-title":"Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis","volume":"96","author":"Schiller Salton","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2025.09.020_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-022-00778-3","article-title":"One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients","volume":"13","author":"Pinana","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cmi.2025.09.020_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1233056","article-title":"Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response","volume":"14","author":"Cernera","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.09.020_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/microorganisms11030755","article-title":"Effect of a fourth dose of mRNA vaccine and of immunosuppression in preventing SARS-CoV-2 breakthrough infections in heart transplant patients","volume":"11","author":"Masetti","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.cmi.2025.09.020_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001537","article-title":"Clinical course, immunogenicity, and efficacy of BNT162b2 mRNA vaccination against SARS-CoV-2 infection in liver transplant recipients","volume":"9","author":"Tan","year":"2023","journal-title":"Transplant Direct"},{"key":"10.1016\/j.cmi.2025.09.020_bib39","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.transproceed.2022.11.001","article-title":"Immunosuppressant and SARS-CoV-2 vaccine antibody response after lung transplantation","volume":"54","author":"Kim","year":"2022","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cmi.2025.09.020_bib40","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3390\/v14091951","article-title":"Serological response and clinical protection of anti-SARS-CoV-2 vaccination and the role of immunosuppressive drugs in a cohort of kidney transplant patients","volume":"14","author":"Biagio","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.09.020_bib41","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/TP.0000000000004105","article-title":"An analysis of serological response and infection outcomes following Oxford-Astrazeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 vaccines in kidney and kidney-pancreas transplants","volume":"106","author":"Asderakis","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2025.09.020_bib42","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3390\/microorganisms10081563","article-title":"Analysis of the specific immune response after the third dose of mRNA COVID-19 vaccines in organ transplant recipients: Possible spike-S1 reactive IgA signature in protection from SARS-CoV-2 infection","volume":"10","author":"Miele","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.cmi.2025.09.020_bib43","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.healun.2022.01.005","article-title":"Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age","volume":"41","author":"Tanner","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cmi.2025.09.020_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265130","article-title":"Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre","volume":"17","author":"Chukwu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2025.09.020_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.180750","article-title":"Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases","volume":"9","author":"Anderson","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.cmi.2025.09.020_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003400","article-title":"COVID-19 Vaccine in immunosuppressed adults with autoimmune rheumatic diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series","volume":"9","author":"Colmegna","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.cmi.2025.09.020_bib47","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/vaccines11111684","article-title":"Older age, a high titre of neutralising antibodies and therapy with conventional DMARDs are associated with protection from breakthrough infection in rheumatoid arthritis patients after the booster dose of anti-SARS-CoV-2 vaccine","volume":"11","author":"Picchianti-Diamanti","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cmi.2025.09.020_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1146841","article-title":"Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections","volume":"14","author":"Egri","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2025.09.020_bib49","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jiph.2022.05.005","article-title":"COVID-19 breakthrough infections in rheumatic diseases patients after vaccination","volume":"15","author":"Alshukairi","year":"2022","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.cmi.2025.09.020_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/antib12020037","article-title":"Serological response to SARS-CoV-2 vaccine in hemodialyzed patients and the association with later COVID-19 positivity","volume":"12","author":"Premuzic","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.cmi.2025.09.020_bib51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/hdi.13005","article-title":"Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients\u2013A prospective observational study","volume":"26","author":"Al-Muhaiteeb","year":"2022","journal-title":"Hemodial Int"},{"key":"10.1016\/j.cmi.2025.09.020_bib52","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/vaccines10101738","article-title":"Long-term dynamic humoral response to SARS-CoV-2 mRNA vaccines in patients on peritoneal dialysis","volume":"10","author":"Quiroga","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cmi.2025.09.020_bib53","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/vaccines10091395","article-title":"Efficacy and safety of COVID-19 vaccine in patients on renal replacement therapy","volume":"10","author":"Frittoli","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cmi.2025.09.020_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jaip.2022.10.046","article-title":"Clinical outcomes, immunogenicity, and safety of BNT162b2 vaccine in primary antibody deficiency","volume":"11","author":"Milota","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.cmi.2025.09.020_bib55","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10875-022-01231-7","article-title":"SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study","volume":"42","author":"Shields","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.cmi.2025.09.020_bib56","article-title":"Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study","volume":"21","author":"Martin","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.cmi.2025.09.020_bib57","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ajh.26951","article-title":"Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms","volume":"98","author":"Jimenez","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2025.09.020_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102249","article-title":"Neutralising antibody responses against SARS-CoV-2 Omicron BA.4\/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): A prospective, multicentre, cohort study","volume":"64","author":"Liu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cmi.2025.09.020_bib59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(23)01180-7","article-title":"Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing","volume":"402","author":"Wijaya","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.09.020_bib60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41409-023-01946-0","article-title":"SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination","volume":"58","author":"Pinana","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2025.09.020_bib61","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijid.2022.10.005","article-title":"Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: A systematic review and meta-analysis","volume":"124","author":"Yin","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2025.09.020_bib62","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1038\/s41467-022-32985-8","article-title":"Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity","volume":"13","author":"Scurr","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2025.09.020_bib63","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(21)02096-1","article-title":"Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients","volume":"398","author":"Prendecki","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2025.09.020_bib64","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2025.09.020_bib65","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.immuni.2022.07.005","article-title":"Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination","volume":"55","author":"Gao","year":"2022","journal-title":"Immunity"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25004719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:09:17Z","timestamp":1773932957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25004719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1198743X25004719"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.09.020","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between COVID-19 vaccine immunogenicity and protection against infection and severe disease in clinically vulnerable patient populations: a systematic review and meta-analysis of observational studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}